NeoGenomics (NASDAQ:NEO) Releases Results, Beats Estimates By $0.04 EPS
NeoGenomics (NASDAQ:NEO) released its quarterly earnings results on Thursday. The medical research company reported $0.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.04, MarketWatch Earnings reports. NeoGenomics had a return on equity of 5.27% and a net margin of 1.96%. The business had revenue of $106.90 million during the quarter, compared to analysts’ expectations of $104.25 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. The company’s quarterly revenue was up 39.4% compared to the same quarter last year. NeoGenomics updated its FY 2020
Pre-Market guidance to EPS.
NASDAQ:NEO opened at $28.33 on Friday. NeoGenomics has a 1 year low of $18.00 and a 1 year high of $34.97. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.05 and a current ratio of 4.55. The stock has a fifty day moving average price of $32.18 and a two-hundred day moving average price of $26.08. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of 404.77 and a beta of 1.03.
Several equities analysts have issued reports on NEO shares. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Benchmark raised their target price on shares of NeoGenomics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday. Needham & Company LLC lifted their target price on shares of NeoGenomics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Friday. First Analysis upgraded shares of NeoGenomics from an “outperform” rating to a “strong-buy” rating and set a $35.00 price target on the stock in a research note on Friday. Finally, BidaskClub lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $27.29.
In other NeoGenomics news, CAO Kathryn B. Mckenzie sold 8,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $26.37, for a total transaction of $210,960.00. Following the sale, the chief accounting officer now directly owns 10,273 shares in the company, valued at approximately $270,899.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.80% of the stock is currently owned by company insiders.
About NeoGenomics
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Read More: Why are gap-down stocks important?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source